1. Home
  2. LYEL vs CBFV Comparison

LYEL vs CBFV Comparison

Compare LYEL & CBFV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

SELL

Current Price

$13.64

Market Cap

195.8M

Sector

Health Care

ML Signal

SELL

Logo CB Financial Services Inc.

CBFV

CB Financial Services Inc.

SELL

Current Price

$40.39

Market Cap

189.9M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
LYEL
CBFV
Founded
2018
1901
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
195.8M
189.9M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
LYEL
CBFV
Price
$13.64
$40.39
Analyst Decision
Buy
Buy
Analyst Count
8
3
Target Price
$37.63
★ $45.00
AVG Volume (30 Days)
★ 212.6K
8.0K
Earning Date
11-04-2026
10-26-2026
Dividend Yield
N/A
★ 2.79%
EPS Growth
N/A
★ N/A
EPS
N/A
★ 2.53
Revenue
$36,000.00
★ $43,557,000.00
Revenue This Year
N/A
$15.13
Revenue Next Year
N/A
$7.98
P/E Ratio
★ N/A
$15.94
Revenue Growth
N/A
★ N/A
52 Week Low
$7.20
$33.40
52 Week High
$45.00
$41.31

Technical Indicators

Market Signals
Indicator
LYEL
CBFV
Relative Strength Index (RSI) 54.63 51.63
Support Level $12.25 $35.95
Resistance Level $14.97 $41.31
Average True Range (ATR) 1.67 0.99
MACD -0.18 -0.16
Stochastic Oscillator 43.74 43.36

Price Performance

Historical Comparison
LYEL
CBFV

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

About CBFV CB Financial Services Inc.

CB Financial Services Incis a bank holding company headquartered in Carmichaels, Pennsylvania. The company had one reportable segment, community banking services. The Bank also has a loan production office in Allegheny County, a loan production office and a corporate center in Washington County, and an operations center in Greene County, Pennsylvania. The Bank is a community-oriented institution offering residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a variety of deposit products for individuals and businesses in its market area.

Share on Social Networks: